Abstract
Aim
We retrospectively investigated the efficacy and safety of combination chemotherapy with 5-fluorouracil (5-FU) and cisplatin plus docetaxel (DCF) as preoperative chemotherapy.
Methods
One hundred and seven patients were diagnosed with esophageal cancer of clinical stage II and III (except T4) from March 2007 to June 2009. Among these, five patients who had extensive locoregional lymph node metastases underwent preoperative DCF chemotherapy.
Results
Median age of the five patients was 59 (51–67) years, and all were men with clinical stage III esophageal cancer. The best overall responses were 80% with partial response (PR) and 20% with stable disease (SD). Histological response of grade 1b and more was also 80%. The hematologic toxicities included grade 3 leucopenia in 80% of patients; grade 3 or 4 neutropenia was observed in all patients. Febrile neutropenia occurred in 20% of patients. Nonhematologic toxicities included grade 3 anorexia in 80% of patients. The operations were not postponed due to any adverse events. Postoperative complications included pneumonia, pneumothorax, and cervical lymphatic leakage (one case each). No chemotherapy-related postoperative complications were observed. Median follow-up of surviving patients was 51.5 (33.9–56.4) months. Disease-free survival times were 12.1, 30.9, 48.0, 49.0, and 54.0 months, respectively. Overall survival times were 28.9, 33.9, 51.0, 52.1, and 56.4 months, respectively.
Conclusions
The response rate of preoperative DCF was 80%, and toxicities were tolerated with support therapies such as granulocyte colony-stimulating factor (G-CSF) and dexamethasone. We therefore concluded that this preoperative treatment might be a promising strategy for patients who have extensive regional lymph node metastases.
Similar content being viewed by others
References
Kuwano H, Nishimura Y, Ohtsu A, Kato H, Kitagawa Y, Tamai S, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition: part I Edited by the Japan Esophageal Society. Esophagus. 2008;5:61–73.
Kuwano H, Nishimura Y, Ohtsu A, Kato H, Kitagawa Y, Tamai S, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition: part II Edited by the Japan Esophageal Society. Esophagus. 2008;5:117–32.
Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011. [Epub ahead of print] PMID: 21879261.
Matsutani T, Sasajima K, Maruyama H, Futami R, Tsuchiya Y, Kashiwabara M, et al. Evaluation of second-line chemotherapy with docetaxel/5-fluorouracil/cisplatin for unresectable or recurrent squamous cell carcinoma of the esophagus. Jpn J Gastroenterol Surg. 2008;41:458–63 (in Japanese with English abstract).
Minamide J, Aoyama N, Takada K, Oota Y. Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer. Gan To Kagaku Ryoho. 2007;34(1):49–52 (in Japanese with English abstract).
Cutsem EV, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.
Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H. A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU. Gan To Kagaku Ryhoho. 2008;35(8):1375–8 (in Japanese with English abstract).
Matsutani T, Sasajima K, Maruyama H, Suzuki S, Kobayashi Y, Tajiri T. A case of postoperative thoracic and para aorta lymph node recurrence in esophageal carcinoma responding completely to chemoradiotherapy using docetaxel, nedaplatin and 5-fluorouracil. Rinsho Geka. 2009;64(6):837–40 (in Japanese).
Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease and oncology group trial (KDOG 0501). Radiother Oncol. 2008;87:398–404.
Vermorken JB, Remenar E, Herpen CV, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.
Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.
Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part II and III. Esophagus. 2009;6:71–94.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.
Japan Clinical Oncology Group Data Center, National Cancer Center, National Cancer Center Hospital Residents, Japan Society of Clinical Oncology. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol. 2004;9(Suppl 3):1–82 (in Japanese).
Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infec Dis. 2004;39(Suppl 1):49–52.
Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172–6.
Minamide J, Koizumi H, Aoyama N, Ozawa Y, Tokunaga M, Fukano F, et al. Study on safety and finding of direct effect of preoperative cisplatin and 5-fluorouracil combination chemotherapy in intensive treatment for esophageal carcinoma. Jpn J Gastroenterol Surg. 1994;27:2384–90 (in Japanese with English abstract).
Honda M, Miura A, Kato T, Miyamoto M, Izumi Y. Evaluation of combination chemotherapy with 5-FU, doxorubicin and CDDP in patients with advanced esophageal cancer. Nihon Kikan Shokudoka Gakkai Kaiho. 2008;59:539–44 (in Japanese with English abstract).
Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2002. Esophagus. 2010;7:7–22.
Hirao M, Ando N, Tsujinaka T, Udagawa H, Yano M, Yamana H, et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 2011;98:1735–41.
Yoshida T, Seike J, Miyoshi T, Yamai H, Takechi H, Yuasa Y, et al. Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus. Esophagus. 2010;7:95–100.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tanaka, T., Kinoshita, Y., Udagawa, H. et al. Efficacy and safety of docetaxel/cisplatin/5-fluorouracil preoperative combination chemotherapy in esophageal cancer patients with extended lymph node metastases. Esophagus 9, 99–104 (2012). https://doi.org/10.1007/s10388-012-0312-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10388-012-0312-1